C
Christopher J. Packard
Researcher at Glasgow Royal Infirmary
Publications - 236
Citations - 25953
Christopher J. Packard is an academic researcher from Glasgow Royal Infirmary. The author has contributed to research in topics: Lipoprotein & Very low-density lipoprotein. The author has an hindex of 72, co-authored 236 publications receiving 24985 citations.
Papers
More filters
Journal ArticleDOI
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group
J. Shepherd,Stuart M. Cobbe,Ian Ford,C. G. Isles,AR Lorimer,Peter W. Macfarlane,J. H. Mckillop,Christopher J. Packard +7 more
TL;DR: Treatment with pravastatin significantly reduced the incidence of myocardial infarction and death from cardiovascular causes without adversely affecting the risk of death from noncardiovascular causes in men with moderate hypercholesterolemia and no history of my Cardiac Infarction.
Journal ArticleDOI
West of Scotland Coronary Prevention Study: Identification of high-risk groups and comparison with other cardiovascular intervention trials
J. Shepherd,Stuart M. Cobbe,AR Lorimer,James H. McKillop,Jane B. Ford,Christopher J. Packard,Peter W. Macfarlane,Chris Isles,MF Oliver,A. F. Lever,BW Brown,Jgg Ledingham,SJ Pocock,BM Rifkind,B. D. Vallance,David Ballantyne,L Anderson,D Duncan,Sharon Kean,A Lawrence,John J. McGrath,K Montgomery,John Norrie,M Percy,E Pomphrey,Andrew J. O. Whitehouse,Peter Cameron,P Parker,F Porteous,L Fletcher,C Kilday,D Shoat,S Latif,James L. Kennedy,M A Bell,R Birrell,M Mellies,J Meyer,W Campbell +38 more
Journal ArticleDOI
Pravastatin and the Development of Diabetes Mellitus Evidence for a Protective Treatment Effect in the West of Scotland Coronary Prevention Study
Dilys J. Freeman,John Norrie,Naveed Sattar,R. Dermot G. Neely,Stuart M. Cobbe,Ian Ford,Christopher G. Isles,A.Ross Lorimer,Peter W. Macfarlane,James H. McKillop,Christopher J. Packard,James Shepherd,Allan Gaw +12 more
TL;DR: By lowering plasma triglyceride levels, pravastatin therapy may favorably influence the development of diabetes, but other explanations, such as the anti-inflammatory properties of this drug in combination with its endothelial effects, cannot be excluded with these analyses.
Journal ArticleDOI
Plasma Leptin and the Risk of Cardiovascular Disease in the West of Scotland Coronary Prevention Study (WOSCOPS)
A M Wallace,Alex D. McMahon,Christopher J. Packard,A Kelly,J. Shepherd,Allan Gaw,Naveed Sattar +6 more
TL;DR: It is shown, for the first time, in a large prospective study that leptin is a novel, independent risk factor for coronary heart disease.
Journal ArticleDOI
Lipoprotein-Associated Phospholipase A2 as an Independent Predictor of Coronary Heart Disease
Christopher J. Packard,Denis St. J. O’Reilly,Muriel J. Caslake,Alex D. McMahon,Ian Ford,Josephine Cooney,Colin H. Macphee,Keith E. Suckling,Mala Krishna,Francis E. Wilkinson,Ann Rumley,Gordon D.O. Lowe +11 more
TL;DR: Elevated levels of lipoprotein-associated phospholipase A2 appear to be a strong risk factor for coronary heart disease, a finding that has implications for atherogenesis and the assessment of risk.